Physician profile
John Sanzone
NPI 1699790980
$1,703.89
in general payments reported to CMS, 2019-2025
30 companies · $96.94 in 2025
The $96.94 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $561 · 2020: $371 · 2021: $423 · 2022: $14.11 · 2023: $205 · 2024: $32.51 · 2025: $96.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $334.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $297.81 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Coloplast Corp | $174.51 | 2019-2023 | Titan |
| Bayer Healthcare Pharmaceuticals INC. | $151.97 | 2019-2025 | |
| Boston Scientific Corporation | $143.04 | 2023 | Rezum Generator |
| Astellas Pharma US INC | $134.64 | 2019-2020 | |
| Myovant Sciences INC. | $82.40 | 2021 | |
| Amgen INC. | $72.12 | 2019-2020 | |
| Pfizer INC. | $68.10 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $61.99 | 2020-2021 | |
| Dendreon Pharmaceuticals LLC | $58.22 | 2019-2020 | |
| Tolmar Pharmaceuticals, INC. | $51.00 | 2019-2022 | |
| Janssen Biotech, INC. | $38.46 | 2019-2021 | |
| Allergan, INC. | $38.15 | 2019 | |
| Acerus Pharmaceuticals Corporation | $37.34 | 2020-2021 | |
| Urovant Sciences INC | $29.47 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clarus Therapeutics INC. | $27.00 | 2021 | |
| Olympus America INC. | $24.51 | 2025 | Soltive |
| Medtronic USA, INC. | $23.48 | 2020 | |
| 180 Medical, INC. | $22.28 | 2021 | |
| Seapearl East, INC | $19.07 | 2023 | |
| Procept Biorobotics Corporation | $18.39 | 2019 | |
| Rochester Medical Corporation | $17.84 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $16.27 | 2021 | |
| C. R. Bard, INC. & Subsidiaries | $16.07 | 2025 | Bard Urinary Drainage Bag |
| Blue Earth Diagnostics | $14.51 | 2019 | |
| Zyla Life Sciences, INC. | $13.98 | 2019 | |
| Ferring Pharmaceuticals INC. | $13.86 | 2019 | |
| Merck Sharp & Dohme LLC | $13.03 | 2021 | |
| Aytu Biopharma, INC. | $12.38 | 2020 | |
| Therapeuticsmd, INC. | $12.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Sanzone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.